1 Short Title: Enzalutamide Vaccine in mCRPC NIH Protocol #: 13-C-0146 OSP #: 1301-1204 Version Date: March 29, 2022 IBC #: RD-13-I-11 NCT #: NCT01867333 Title: A Randomized Phase II Trial Combining Vaccine Therapy with PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men with Metastatic Castration Resistant Prostate Cancer NCI Principal Investigator: Ravi Madan, M.D. Genitourinary Malignancies Branch, CCR, NCI 10 Center Drive Building 10, Room 3-4460 Bethesda, MD 20892 Phone: 301-480-7168 Fax: (301) 480-5094 Email: madanr@mail.nih.gov Investigational Agent: Drug Name: Enzalutamide PROSTVAC-V/F IND Number: 15455 15455 Sponsor: Center for Cancer Research, NCI Center for Cancer Research, NCI Manufacturer: Medivation and Astellas, Inc. Bavarian Nordic, Inc.